Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.
Hansa Biopharma secured $70 million in non-dilutive financing, OSE secured $300 million in funding while CN Bio opened a new contract research facility and more global biopharma news.
Eye surgery robotics startup ForSight raises $10M
Israel-based ForSight Robotics announced today that it has raised $10 million for what it has deemed a “mega-seed round.” Led by Eclipse Ventures and Mithril Capital, the round will go toward expanding the company’s headcount and global reach, as it looks to bring its offerings to international markets, pending the sorts of regulatory approvals that go into launching a robotic surgery platform.
The company’s surgical platform is designed specifically for ophthalmological (eye) surgeries a category requiring a great deal of precision. It’s also one in great demand. The company cites a recent study from the British Journal of Ophthalmology, putting the number of qualified eye surgeons at around 72 per million people in developed nations and a mere 3.7 surgeons per million in developing countries.